search

Active clinical trials for "Astrocytoma"

Results 1-10 of 370

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade...

High-grade GliomaOligodendroglioma2 more

This is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma.

Recruiting32 enrollment criteria

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

High Grade Astrocytic TumorRecurrent Glioblastoma2 more

This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may kill more tumor cells in patients with recurrent glioblastoma.

Recruiting49 enrollment criteria

PARP Inhibition for Gliomas (PI-4G or π4g)

Recurrent GlioblastomaRecurrent Astrocytoma2 more

The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.

Recruiting31 enrollment criteria

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

Malignant Glioma of BrainAstrocytoma12 more

This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.

Recruiting32 enrollment criteria

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma...

Low Grade AstrocytomaLow Grade Glioma2 more

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs that work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will also examine if treatment with selumetinib improves the quality of life for subjects who take it.

Recruiting57 enrollment criteria

HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

GlioblastomaAnaplastic Astrocytoma

Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).

Recruiting33 enrollment criteria

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed...

Anaplastic AstrocytomaAnaplastic Astrocytoma6 more

This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib after radiation therapy may work better than treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade glioma.

Recruiting52 enrollment criteria

Pediatric Long-Term Follow-up and Rollover Study

Diffuse AstrocytomaAnaplastic Astrocytoma22 more

A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

Recruiting18 enrollment criteria

The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients....

GlioblastomaGlioblastoma Multiforme6 more

The trial is designed as a multicenter randomized controlled study. 246 patients with presumed Glioblastoma Multiforme in eloquent areas on diagnostic MRI will be selected by the neurosurgeons according the eligibility criteria (see under). After written informed consent is obtained, the patient will be randomized for an awake craniotomy (AC) (+/-123 patients) or craniotomy under general anesthesia (GA) (+/-123 patients), with 1:1 allocation ratio. Under GA the amount of resection of the tumour has to be performed within safe margins as judged by the surgeon during surgery. The second group will be operated with an awake craniotomy procedure where the resection boundaries for motor or language functions will be identified by direct cortical and subcortical stimulation. After surgery, the diagnosis of GBM will have to be histologically confirmed. If GBM is not histologically confirmed, patients will be considered off-study and withdrawn from the study. These patients will be followed-up according to standard practice. Thereafter, patients will receive the standard treatment with concomitant Temozolomide and radiation therapy and standard follow up. Total duration of the study is 5 years. Patient inclusion is expected to take 4 years. Follow-up is 1 year after surgery. Statistical analysis, cost benefit analysis and article writing will take 3 months.

Recruiting16 enrollment criteria

Surgical Nivolumab And Ipilimumab For Recurrent GBM

GlioblastomaGBM2 more

This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the study drugs involved in this study are: Nivolumab Ipilimumab Placebo (IV solution with no medicine) Zr-89 Crefmirlimab berdoxam (optional sub-study)

Recruiting60 enrollment criteria
12...37

Need Help? Contact our team!


We'll reach out to this number within 24 hrs